Streetwise Regenerative Medicine Articles

Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market'

Research Report
Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential. read more >

Analyst's $70 Target Price on Regenerative Medicine Biotech More than a Triple

One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine." read more >
Showing Results: 1 to 2 of 2

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe